Angiopoietins as Potential Targets in Management of Retinal Disease

Arshad M Khanani1 Sierra Eye Associates, Reno, NV, USA;2 The University of Nevada, Reno School of Medicine, Reno, NV, USACorrespondence[email protected]

Matthew W Russell3 Center for Ophthalmic Bioinformatics, Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA;4 Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH, USA

Aamir A Aziz1 Sierra Eye Associates, Reno, NV, USA;2 The University of Nevada, Reno School of Medicine, Reno, NV, USA

Carl J Danzig5 Rand Eye Institute, Deerfield, FLA, USA;6 Florida Atlantic University, Charles E. Schmidt College of Medicine, Boca Raton, FL, USA

Christina Y Weng7 Baylor College of Medicine, Houston, TX, USA

David A Eichenbaum8 Retina Vitreous Associates of Florida, St Petersburg, FLA, USA;9 University of South Florida Morsani College of Medicine, Tampa, FLA, USA

Rishi P Singh3 Center for Ophthalmic Bioinformatics, Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA;4 Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH, USA

show all

Abstract

The Ang/Tie2 pathway complements VEGF-mediated activity in retinal vascular diseases such as DME, AMD, and RVO by decreasing vascular integrity, increasing neovascularization, and increasing inflammatory signaling. Faricimab is a bispecific antibody that has been developed as an inhibitor of both VEGF and Ang2 that has shown positive results in phase I, II and III trials. Recent Year 1 data from phase III clinical trials YOSEMITE, RHINE, TENAYA, and LUCERNE have confirmed the efficacy, safety, durability, and superiority of faricimab in patients with DME and nAMD. Faricimab, if approved, may significantly decrease treatment burden in patients with retinal vascular diseases to a greater extent than would current standard of care anti-VEGF injections.

Keywords:

Disclosure

AK: Consultant: Adverum, Aerpio, Allergan, Chengdu Kanghong, DORC, Genentech, Inc., Kato, Kodiak, Novartis, Gemini, Graybug, Gyroscope, Opthea, Oxurion, PolyPhotonix, Recens Medical, Regenxbio, Roche

Research support: Adverum, Alkahest, Allegro, Allergan, Chengdu Kanghong, Gemini, Genentech, Inc., Gyroscope, Iveric Bio, NGM, Neurotech, Kodiak, Novartis, Opthea, Oxurion, Regenxbio, Recens Medical, Roche

Lecture fees: Allergan, Genentech, Novartis

CD: Consultant: Genentech, Roche, Regeneron, Novartis, IvericBio

Research support: Genentech, Roche, Regeneron, Novartis, IvericBio, Kodiak, Adverum, Gyroscope

Lecture fees: Novartis, DORC

CYW: Consultant: Allergan/AbbVie, Alcon, Alimera Sciences, Novartis, Regeneron, REGENXBIO, Genentech, DORC

DE: Consultant: Genentech, Regeneron, Allergan, Novartis, Notal Vision, EyePoint, Gyroscope, Kodiak, RecensMedical, DORC, IvericBio, Apellis, KKR, Regenxbio, Bausch & Lomb

Research support: AsclepiX, Genentech, Bayer, Novartis, Alimera, Opthea, Ocular Therapeutix, EyePoint, Mylan, Chengdu, Gemini, Gyroscope, Kodiak, NGM, RecensMedical, Alkahest, Ionis, IvericBio, Regenxbio

Lecture fees: Genentech, Bayer, Allergan, Novartis, EyePoint, DORC, Apellis

Equity/Stockholder: Clearside, US Retina, Hemera Biopharmaceuticals, Boston Image Reading Center, Network Eye

Founder: Network Eye

RPS: Consultant: Regeneron, Genentech, Alcon, Novartis, Asclepix, Gyroscope, Bausch and Lomb.

Research support: Apellis, NGM Biopharma

The authors report no other conflicts of interest in this work.

Angiopoietins as Potential Targets in Management of Retinal Disease

Information for

Open access

Opportunities

Help and information

Angiopoietins as Potential Targets in Management of Retinal Disease

Abstract

Disclosure

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature